GlassScriptPhysician profile
Jonathan J Wilson
NPI 1790959971
$2,828.42
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $344 · 2021: $545 · 2022: $408 · 2023: $692 · 2024: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.63 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.73 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $277.46 | 2020-2024 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $204.32 | 2020-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $193.23 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $179.46 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $168.91 | 2019-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.54 | 2021-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $141.61 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $141.19 | 2019-2023 | |
| Amgen INC. | $114.95 | 2019-2022 | |
| Corcept Therapeutics | $106.49 | 2023-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $103.55 | 2020-2024 | Airsupra, Farxiga |
| Sanofi Pasteur INC. | $92.94 | 2019-2023 | |
| Lilly USA, LLC | $92.51 | 2019-2023 | Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $76.51 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.74 | 2021-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Phadia US INC. | $49.35 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $43.19 | 2019 | |
| Collegium Pharmaceutical, INC. | $29.50 | 2023-2024 | Belbuca, Xtampza |
| Nevro Corp. | $28.19 | 2023 | Senza |
| Exact Sciences Corporation | $26.45 | 2024 | Cologuard Collection Kit |
| Medicomp INC | $25.32 | 2024 | Telepatch Cardiac Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.16 | 2019-2020 | |
| Coopersurgical, INC. | $18.17 | 2022 | |
| Neurocrine Biosciences, INC. | $17.08 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $16.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.